학술논문
Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis.
Document Type
Article
Author
Source
Subject
*MULTIPLE sclerosis
*THYROID diseases
*GRAVES' disease
*TYPE I interferons
*
*
*
Language
ISSN
1050-7256
Abstract
Immunomodulatory treatments, particularly the new generation anti-CD20 drugs, may provide a potentially novel physiopathological approach to treatment of GD and warrant further study. B Dear Editor: b Graves' disease (GD) is a frequent complication of immune reconstitution after immunomodulatory treatment for multiple sclerosis (MS). Graves' disease induced by alemtuzumab in relapsing-remitting multiple sclerosis patients: An observational study in a reference center. [Extracted from the article]